UK AND IRELAND 
For more information:
With worldwide headquarters in Atlanta, CIBA VISION is a global leader in research, development and manufacturing of optical products and services, including contact lenses and lens care products. CIBA VISION products are available in more than 70 countries. For more information, see About Us. CIBA VISION is the eye care unit of Novartis AG (NYSE:NVS), a world leader in offering medicines to protect health, cure disease and improve well-being. Our goal is to discover, develop and successfully market innovative products to treat patients, ease suffering and enhance the quality of life. Novartis is the only company with leadership positions in both patented and generic pharmaceuticals. We are strengthening our medicine-based portfolio, which is focused on strategic growth platforms in innovation-driven pharmaceuticals; high-quality, low-cost generics; human vaccines and leading self-medication OTC brands. In 2005, the Group’s business achieved net sales of USD 32.2 billion and net income of USD 6.1 billion. Group companies employees approximately 96,000 people and operate in over 140 countries around the world. For more information, please visit http://www.novartis.com.
With worldwide headquarters in Atlanta, CIBA VISION is a global leader in research, development and manufacturing of optical products and services, including contact lenses and lens care products. CIBA VISION products are available in more than 70 countries. For more information, see About Us. CIBA VISION is the eye care unit of Novartis AG (NYSE:NVS), a world leader in offering medicines to protect health, cure disease and improve well-being. Our goal is to discover, develop and successfully market innovative products to treat patients, ease suffering and enhance the quality of life. Novartis is the only company with leadership positions in both patented and generic pharmaceuticals. We are strengthening our medicine-based portfolio, which is focused on strategic growth platforms in innovation-driven pharmaceuticals; high-quality, low-cost generics; human vaccines and leading self-medication OTC brands. In 2005, the Group’s business achieved net sales of USD 32.2 billion and net income of USD 6.1 billion. Group companies employees approximately 96,000 people and operate in over 140 countries around the world. For more information, please visit http://www.novartis.com.
Choose the year to view the Press Releases.
For all media enquiries, please contact:
Simon Grist
020 7413 3081
sgrist@hillandknowlton.com
Gemma Maguire
020 7413 3516
gmaguire@hillandknowlton.com
Lydia Haddrell
020 7413 3027
lhaddrell@hillandknowlton.com